A Review on Advances in F-FDG PET/CT Radiomics Standardisation and Application in Lung Disease Management

Overview

Journal Insights Imaging

Publisher Springer

Specialty Radiology

Date 2022 Feb 6

PMID 35124733

Authors

Noushin Anan

Rafidah Zainon

Mahbubunnabi Tamal

Affiliations

Soon will be listed here.

Abstract

Radiomics analysis quantifies the interpolation of multiple and invisible molecular features present in diagnostic and therapeutic images. Implementation of 18-fluorine-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) radiomics captures various disorders in non-invasive and high-throughput manner. F-FDG PET/CT accurately identifies the metabolic and anatomical changes during cancer progression. Therefore, the application of F-FDG PET/CT in the field of oncology is well established. Clinical application of F-FDG PET/CT radiomics in lung infection and inflammation is also an emerging field. Combination of bioinformatics approaches or textual analysis allows radiomics to extract additional information to predict cell biology at the micro-level. However, radiomics texture analysis is affected by several factors associated with image acquisition and processing. At present, researchers are working on mitigating these interrupters and developing standardised workflow for texture biomarker establishment. This review article focuses on the application of F-FDG PET/CT in detecting lung diseases specifically on cancer, infection and inflammation. An overview of different approaches and challenges encountered on standardisation of F-FDG PET/CT technique has also been highlighted. The review article provides insights about radiomics standardisation and application of F-FDG PET/CT in lung disease management.

Citing Articles

Differentiating second primary lung cancer from pulmonary metastasis in patients of single solitary pulmonary lesion with extrapulmonary tumor using multiparametric analysis of FDG PET/CT.

Liu H, Meng X, Wang G, Yao S, Wang Y, Wang R Ann Nucl Med. 2025; .

PMID: 40042775 DOI: 10.1007/s12149-025-02034-7.

A review on optimization of Wilms tumour management using radiomics.

Alhashim M, Anan N, Tamal M, Altarrah H, Alshaibani S, Hill R BJR Open. 2024; 6(1):tzae034.

PMID: 39483333 PMC: 11525052. DOI: 10.1093/bjro/tzae034.

Multicentric study on the reproducibility and robustness of PET-based radiomics features with a realistic activity painting phantom.

Kallos-Balogh P, Vas N, Toth Z, Szakall S, Szabo P, Garai I PLoS One. 2024; 19(10):e0309540.

PMID: 39446842 PMC: 11500893. DOI: 10.1371/journal.pone.0309540.

PET radiomics in lung cancer: advances and translational challenges.

Zhang Y, Huang W, Jiao H, Kang L EJNMMI Phys. 2024; 11(1):81.

PMID: 39361110 PMC: 11450131. DOI: 10.1186/s40658-024-00685-5.

Case report: diagnosis and treatment of advanced high-grade serous ovarian carcinoma aided by Ga-FAPI PET/MR scan.

Zhu M, Sun S, Huang L, Chen M, Cai J, Wang Z Am J Nucl Med Mol Imaging. 2024; 14(1):72-77.

PMID: 38500744 PMC: 10944375.

References

Cook G, Azad G, Owczarczyk K, Siddique M, Goh V . Challenges and Promises of PET Radiomics. Int J Radiat Oncol Biol Phys. 2018; 102(4):1083-1089. PMC: 6278749. DOI: 10.1016/j.ijrobp.2017.12.268. View

Joober R, Schmitz N, Annable L, Boksa P . Publication bias: what are the challenges and can they be overcome?. J Psychiatry Neurosci. 2012; 37(3):149-52. PMC: 3341407. DOI: 10.1503/jpn.120065. View

Zander T, Scheffler M, Nogova L, Kobe C, Engel-Riedel W, Hellmich M . Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol. 2011; 29(13):1701-8. DOI: 10.1200/JCO.2010.32.4939. View

Kirienko M, Cozzi L, Rossi A, Voulaz E, Antunovic L, Fogliata A . Ability of FDG PET and CT radiomics features to differentiate between primary and metastatic lung lesions. Eur J Nucl Med Mol Imaging. 2018; 45(10):1649-1660. DOI: 10.1007/s00259-018-3987-2. View

Chicklore S, Goh V, Siddique M, Roy A, Marsden P, Cook G . Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging. 2012; 40(1):133-40. DOI: 10.1007/s00259-012-2247-0. View

Chang S, Nguyen D, Raptis C, Menias C, Zhou G, Wang-Gillam A . Natural history of preoperative subcentimeter pulmonary nodules in patients with resectable pancreatic adenocarcinoma: a retrospective cohort study. Ann Surg. 2014; 261(5):970-5. DOI: 10.1097/SLA.0000000000000719. View

Graham M, Badawi R, Wahl R . Variations in PET/CT methodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey. J Nucl Med. 2011; 52(2):311-7. PMC: 3889016. DOI: 10.2967/jnumed.109.074104. View

Chen S, Harmon S, Perk T, Li X, Chen M, Li Y . Diagnostic classification of solitary pulmonary nodules using dual time F-FDG PET/CT image texture features in granuloma-endemic regions. Sci Rep. 2017; 7(1):9370. PMC: 5571049. DOI: 10.1038/s41598-017-08764-7. View

Parmar C, Grossmann P, Bussink J, Lambin P, Aerts H . Machine Learning methods for Quantitative Radiomic Biomarkers. Sci Rep. 2015; 5:13087. PMC: 4538374. DOI: 10.1038/srep13087. View

10.

Huang T, Wang Y . Deformation effect on SUVmax changes in thoracic tumors using 4-D PET/CT scan. PLoS One. 2013; 8(3):e58886. PMC: 3597593. DOI: 10.1371/journal.pone.0058886. View

11.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

12.

Gambhir S . Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002; 2(9):683-93. DOI: 10.1038/nrc882. View

13.

Schwyzer M, Martini K, Benz D, Burger I, Ferraro D, Kudura K . Artificial intelligence for detecting small FDG-positive lung nodules in digital PET/CT: impact of image reconstructions on diagnostic performance. Eur Radiol. 2019; 30(4):2031-2040. DOI: 10.1007/s00330-019-06498-w. View

14.

Buckler A, Bresolin L, Reed Dunnick N, Sullivan D . A collaborative enterprise for multi-stakeholder participation in the advancement of quantitative imaging. Radiology. 2011; 258(3):906-14. DOI: 10.1148/radiol.10100799. View

15.

Rajendran J, Mankoff D, OSullivan F, Peterson L, Schwartz D, Conrad E . Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 2004; 10(7):2245-52. DOI: 10.1158/1078-0432.ccr-0688-3. View

16.

Du D, Gu J, Chen X, Lv W, Feng Q, Rahmim A . Integration of PET/CT Radiomics and Semantic Features for Differentiation between Active Pulmonary Tuberculosis and Lung Cancer. Mol Imaging Biol. 2020; 23(2):287-298. DOI: 10.1007/s11307-020-01550-4. View

17.

van Timmeren J, Cester D, Tanadini-Lang S, Alkadhi H, Baessler B . Radiomics in medical imaging-"how-to" guide and critical reflection. Insights Imaging. 2020; 11(1):91. PMC: 7423816. DOI: 10.1186/s13244-020-00887-2. View

18.

Ganeshan B, Miles K . Quantifying tumour heterogeneity with CT. Cancer Imaging. 2013; 13:140-9. PMC: 3613789. DOI: 10.1102/1470-7330.2013.0015. View

19.

Meyer M, Ronald J, Vernuccio F, Nelson R, Ramirez-Giraldo J, Solomon J . Reproducibility of CT Radiomic Features within the Same Patient: Influence of Radiation Dose and CT Reconstruction Settings. Radiology. 2019; 293(3):583-591. PMC: 10860741. DOI: 10.1148/radiol.2019190928. View

20.

Suo S, Cheng J, Cao M, Lu Q, Yin Y, Xu J . Assessment of Heterogeneity Difference Between Edge and Core by Using Texture Analysis: Differentiation of Malignant From Inflammatory Pulmonary Nodules and Masses. Acad Radiol. 2016; 23(9):1115-22. DOI: 10.1016/j.acra.2016.04.009. View